Immunization with the tumor-specific MAGE-3 antigen has been shown to induce robust immune responses for patients with metastatic melanoma (147), albeit in a phase III trial the immunostimulatory lipid AS15 failed to improve PFS as an adjuvant treatment strategy in patients with MAGE-A3 positive NSCLC (148). This evidence concerns the gene MAGEA3 and metastatic melanoma.